3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
53
Neoplasms
36
Lung Neoplasms
25
Colorectal Neoplasms
23
Prostatic Neoplasms
17
Uterine Cervical Neoplasms
14
Motor Activity
13
Colonic Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Rectal Neoplasms
9
Anxiety Disorders
9
Urinary Bladder Neoplasms
8
Pancreatic Neoplasms
8
Obesity
8
Melanoma
8
Depression
8
Lymphoma
7
Hematologic Neoplasms
7
Endometrial Neoplasms
7
Vulvar Neoplasms
6
Ovarian Neoplasms
6
Head and Neck Neoplasms
6
Breast Carcinoma In Situ
6
Sarcoma
5
Pain
5
Hematopoietic and Lymphatic System Neoplasm
5
Triple Negative Breast Neoplasms
4
Stomach Neoplasms
4
Papillomavirus Infections
4
Neoplasm Metastasis
4
Interventions
Everolimus
7
Nivolumab
6
Cisplatin
6
Temozolomide
5
Bevacizumab
5
lutetium Lu 177 dotatate
4
Fluorouracil
4
Carboplatin
4
pembrolizumab
3
avelumab
3
atezolizumab
3
Irinotecan
3
Ipilimumab
3
Etoposide
3
Capecitabine
3
surufatinib
2
sintilimab
2
gallium Ga 68 dotatate
2
dostarlimab
2
Radiosurgery
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
PE regimen
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Magnetic Resonance Imaging
2
Immunoglobulin G
2
IFL protocol
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Disulfides
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Neuroendocrine
×
Methods
×
Clear all
NCT04478175
2022-11-17
DParcoursDig
Institut Curie
Phase NA
Completed
30 enrolled